American Journal of Cardiovascular Drugs

, Volume 12, Issue 3, pp 197–206

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups


    • Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC)
  • Arvind Shah
    • Merck Sharp & Dohme Corp.
  • Jianxin Lin
    • Merck Sharp & Dohme Corp.
  • Christine McCrary Sisk
    • Merck Sharp & Dohme Corp.
  • Qian Dong
    • Merck Sharp & Dohme Corp.
  • Darbie Maccubbin
    • Merck Sharp & Dohme Corp.
Original Research Article

DOI: 10.2165/11631530-000000000-00000

Cite this article as:
Bays, H.E., Shah, A., Lin, J. et al. Am J Cardiovasc Drugs (2012) 12: 197. doi:10.2165/11631530-000000000-00000



According to prior analyses, extended-release niacin/laropiprant (ERN/LRPT) consistently reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) and increases high-density lipoprotein cholesterol (HDL-C) levels across a wide range of dyslipidemic patient subgroups.


This analysis examined ERN/LRPT’s consistency across four phase III, randomized, double-blind trials in improving other lipid/lipoprotein parameters associated with cardiovascular risk, across several key dyslipidemic patient subgroups.


In three of the studies, the randomized population included patients with primary hypercholesterolemia or mixed hyperlipidemia; in the remaining study, the population included patients with type 2 diabetes mellitus. The lipid-altering consistency of ERN/LRPT’s efficacy was evaluated versus the predefined comparator (placebo or active control) among key subgroups of sex, race (White, non-White), region (US, ex-US), baseline age (<65 years, ≥65 years), use of statin therapy (yes, no), coronary heart disease (yes, no), risk status (low, multiple, high), and type of hyperlipidemia (primary hypercholesterolemia, mixed dyslipidemia), as well as across baseline LDL-C, HDL-C, and TG levels. The consistency of the treatment effects on lipoprotein(a) [Lp(a)], apolipoprotein B (ApoB), non-HDL-C, ApoA1, and ApoB/ApoA1 ratio was evaluated by examining treatment difference estimates of the percentage change from baseline with 95% confidence intervals.


Treatment with ERN/LRPT produced significantly greater improvements in Lp(a), ApoB, non-HDL-C, ApoA1, and ApoB/ApoA1 ratio compared with placebo/active comparator in each study. These effects were generally consistent across key subgroups within each study.


ERN/LRPT produced lipid-altering efficacy on the parameters evaluated in four controlled studies; these effects were generally consistent across all examined subgroups. ERN/LRPT represents an effective and reliable therapeutic option for the treatment of dyslipidemia in a wide range of patient types.

Clinical Trial Registration

Registered as NCT00269204, NCT00269217, NCT00479388, and NCT00485758.

Copyright information

© Springer International Publishing AG 2012